- Home
- Publications
- Publication Search
- Publication Details
Title
Immune checkpoint inhibitor-induced sarcoidosis-like granulomas
Authors
Keywords
Drug reactions, Melanoma, Immune checkpoint inhibitor, PD-1, CTLA-4, Sarcoidosis-like granuloma
Journal
International Journal of Clinical Oncology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-07-18
DOI
10.1007/s10147-019-01490-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy
- (2018) Randi Woodbeck et al. AMERICAN JOURNAL OF DERMATOPATHOLOGY
- Ipilimumab-Induced Sarcoidosis and Thyroiditis
- (2018) Sravanthi Nandavaram et al. AMERICAN JOURNAL OF THERAPEUTICS
- Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
- (2018) Ranee Mehra et al. BRITISH JOURNAL OF CANCER
- Erythema Nodosum as the Initial Presentation of Nivolumab-Induced Sarcoidosis-Like Reaction
- (2018) Alexandre Laroche et al. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
- Pembrolizumab-induced sarcoidal infusion site reaction
- (2018) Robert J. Smith et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer
- (2018) Nicholas Borcherding et al. JOURNAL OF MOLECULAR BIOLOGY
- Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission
- (2018) N. Yatim et al. REVUE DE MEDECINE INTERNE
- Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy
- (2018) Leo L. Wang et al. JAMA Dermatology
- Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event
- (2018) Mizuki Nishino et al. Cancer Immunology Research
- Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients
- (2018) Michael T. Tetzlaff et al. Journal for ImmunoTherapy of Cancer
- Biomarkers for Immune Checkpoint Inhibitors in Melanoma
- (2018) Shigehisa Kitano et al. Frontiers in Oncology
- Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
- (2018) Irena Tan et al. Journal for ImmunoTherapy of Cancer
- FDG PET/CT Course of Pembrolizumab-Associated Multiorgan Sarcoidosis
- (2018) Yang Lu CLINICAL NUCLEAR MEDICINE
- Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis
- (2017) Sébastien Le Burel et al. EUROPEAN JOURNAL OF CANCER
- Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis
- (2017) Anna J. Lomax et al. International Journal of Rheumatic Diseases
- Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma
- (2017) Swathi B. Reddy et al. JOURNAL OF IMMUNOTHERAPY
- Melanoma subtypes demonstrate distinct PD-L1 expression profiles
- (2017) Genevieve J Kaunitz et al. LABORATORY INVESTIGATION
- The Antigenicity of the Tumor Cell — Context Matters
- (2017) Vessela N. Kristensen NEW ENGLAND JOURNAL OF MEDICINE
- EBUS-TBNA Can Distinguish Sarcoid-Like Side Effect of Nivolumab Treatment from Tumor Progression in Non-Small Cell Lung Cancer
- (2017) Ségolène Lainez et al. RESPIRATION
- Pembrolizumab-Induced Extensive Panniculitis and Nevus Regression
- (2017) Sara Burillo-Martinez et al. JAMA Dermatology
- Ipilimumab-Induced Granulomatous Disease Occurring Simultaneously With Disease Progression in a Patient With Metastatic Melanoma
- (2016) Anis Toumeh et al. AMERICAN JOURNAL OF THERAPEUTICS
- Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab
- (2016) S. Cousin et al. ANNALS OF ONCOLOGY
- Pulmonary sarcoid-like granulomatosis induced by nivolumab
- (2016) H. Montaudié et al. BRITISH JOURNAL OF DERMATOLOGY
- Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma
- (2016) François-Xavier Danlos et al. CHEST
- Cutaneous sarcoidosis in a melanoma patient under Ipilimumab therapy
- (2016) L. Martínez Leboráns et al. Dermatologic Therapy
- Neoantigen landscape dynamics during human melanoma–T cell interactions
- (2016) Els M. E. Verdegaal et al. NATURE
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors
- (2016) Belal Firwana et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature
- (2016) Joshua E. Reuss et al. Journal for ImmunoTherapy of Cancer
- Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study
- (2016) Viktor H. Koelzer et al. Journal for ImmunoTherapy of Cancer
- Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
- (2016) Noha Abdel-Wahab et al. PLoS One
- New-Onset Mediastinal and Central Nervous System Sarcoidosis in a Patient with Metastatic Melanoma Undergoing CTLA4 Monoclonal Antibody Treatment
- (2016) Kevin P. Murphy et al. Oncology Research and Treatment
- Differential control of CD4+ T-cell subsets by the PD-1/PD-L1 axis in a mouse model of allergic asthma
- (2015) Jaclyn W. McAlees et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab
- (2014) Rikke Andersen et al. OncoImmunology
- Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy
- (2013) C. Tissot et al. EUROPEAN RESPIRATORY JOURNAL
- Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab
- (2013) Ross B. Reule et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
- (2013) Taku Okazaki et al. NATURE IMMUNOLOGY
- Pulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab
- (2012) Grégoire Berthod et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Alfons JM van den Eertwegh et al. LANCET ONCOLOGY
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission
- (2011) Wouter V. Vogel et al. JOURNAL OF CLINICAL ONCOLOGY
- Sarcoidosis—scientific progress and clinical challenges
- (2011) Edward S. Chen et al. Nature Reviews Rheumatology
- Sarcoidosis and Melanoma: A Referral Center Study of 1,199 Cases
- (2009) Pascal Seve et al. DERMATOLOGY
- CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
- (2009) Erika von Euw et al. Journal of Translational Medicine
- Anti-CTLA4 Monoclonal Antibody Induced Sarcoidosis in a Metastatic Melanoma Patient
- (2008) A. Eckert et al. DERMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started